Background: Field trials are the traditional approach for clinical trials in allergy but are under criticism for lack of standardization as they are affected by uncontrollable parameters such as environmental conditions, pollen counts, or lifestyle. Stationary allergen exposure chambers with a dened concentration of allergens under stable and standardized environmental conditions have been used to overcome these restrictions but have not allowed multicenter studies. We here describe the technical speci cations and validation of a novel mobile pollen chamber speci cally designed for multicenter studies -the GA²LEN chamber. Methods: Two inter-connectable standard-sized container frames were used as a structural basis for the newly developed allergen exposure chamber. One container accommodates an observation room, also used as an o ce, and a changing room. e other container houses the test chamber itself and the technical installations. A customized air condition system was integrated and several environmental sensors were installed in the test chamber. Environmental tests have been performed at various outside conditions. e air ow in the test chamber was designed to prevent unspeci c symptoms. To allow for an individual particle exposure at each seat, a new particle disperse and distribution system was developed, patented and validated. Results: Technical and clinical validation tests have been successfully performed with Phleum pratense, Betula pendula, and mixtures of Dermatophagoides farinae, and Dermatophagoides pteronyssinus. e newly developed particle disperse system enable individual verum and placebo exposure, an even particle distribution at every seating position. e builtin air-conditioner is able to generate a tightly controlled, standard ized and comfortable environment and the air ow did not provoke clinically signicant irritation to lower respiratory tract, nose, or eyes. e chamber transportation has proven to be exible and cost-e ective. Conclusion: e GA 2 LEN chamber provides a novel mobile exposure chamber technology for research and clinical trials allowing a fast, a ordable, and standardized multicenter approach.
Introduction
e prevalence of allergic diseases is increasing in industrial as well as in developing nations, resulting in more than 20 % of the world population being a ected [1] . However, they are o en trivialized and undertreated leading to decreased quality of life and high avoidable medical and socioeconomic costs [2, 3] . e high diversity of symptom-elicit- ing allergens, individual threshold levels, and different phenotypes of the disease remain a constant challenge, both in clinical care as well as in research. Especially in inhalant allergies such as allergic rhinitis, allergic rhinoconjunctivitis or allergic asthma, changing environmental factors are di cult to overcome on the path to standardized approaches, as is requested in evidence-based medicine [4] . Clinical trials in inhalant allergies are traditionally conducted while relying on natural allergen exposure in the eld trial setting. e individual aeroallergen exposure within these trials is in uenced by the respective subject's lifestyle and residential situation as well as environmental factors [5, 6, 7] . Furthermore, the reproducibility and comparability of such clinical trials are a ected and biased by the variability and lack of control of airborne allergens, for instance pollen counts, which are subject to local, seasonal, and diurnal variations [8, 9, 10] . Allergen exposure chambers (AECs) have been developed to overcome such di culties in eld trials by o ering de ned, stable, and reproducible allergen exposures under highly standardized environmental conditions. As an additional bene t they allow controlled symptom scoring and measurements as well as a minimized use of rescue medication [11, 12, 13] . AECs have been in use for decades and have undergone technical improvements in recent years. However, the chambers currently available are mainly large and immobile, and partially use technology with high air ow to ventilate the particles in the chamber [14, 15] .
In 2004, the Global Allergy and Asthma European Network (GA 2 LEN) was founded under the sixth framework program of the European Union to initiate a joint e ort to improve Europe's allergy research and clinical care capabilities, and reduce the burden of allergic diseases by standardizing disease management. In 2012, the GA 2 LEN annual conference was dedicated to the topic of how to better standardize clinical trials in allergy, resulting in the call for the development of a novel mobile chamber solution.
is mobile allergen chamber shall allow for multicenter trials utilizing exactly the same technology and overcome the present technical drawbacks, e. g. irritation of eyes and airways by strong air ow, as well as nocebo and placebo e ects as all participants are provoked in the same way in one test run [16] . For the purpose of this development, GA 2 LEN initiated the idea to found a new company and made an open call for industrial partners to join in. As a result, the company Mobile Chamber Experts GmbH (Berlin, Germany) was founded involving the three industrial partners Allergopharma GmbH & Co. KG (Reinbek, Germany), Laboratorios LETI S.L. (Barcelona, Spain) and Stallergenes Greer (London, UK). In addition, the engineering company Bluestone Technology GmbH (Woerrstadt, Germany) was recruited to build a custom-made solution according to the required demands [7, 17] : -A cost-e ective exposure system allowing multicenter exposure chamber trials. -Standardized exposure tests at every site -Allow for all relevant aeroallergens to be used -Induction of comparable symptom scores in the unselected atopic population compared to natural exposure -Enable fast turnaround times -Avoid irritant factors (e. g. recognizable air ow) -Enable an even particle distribution at every seating position -Allow placebo and verum exposure simultaneously in one run -Monitor and possibly modify PM 10 , PM 2.5 , O 3 , or CO 2 concentrations in order to mimic inner city pollution -Comply with all EU country-speci c regulations
Methods
General chamber setup e GA 2 LEN chamber is designed as two standard 24-feet-high cube containers forming an interconnected unit of 7.45 m × 4.90 m × 2.86 m when placed side by side (see Fig. 1 ).
For a chamber to be used at various trial sites, transportation and situating exibility is crucial. Basing the chamber design on standard-sized container frames allows for standard transportation methods by truck, ship, or train without the need for special transportation permits (see Fig 2) . is also allows for loading/unloading procedures by machinery already available everywhere, such as a truck crane, reach-stacker and heavy fork li , or, in certain situations, by way of a mobile crane.
To ensure operability of the GA 2 LEN chamber at a maximum number of trial sites, minimal requirements to the onsite situation were de ned, whereas the system had to be as autarkic as possible. e unit requires only three 400V 32A connections provided by either a local installation or an external generator to be fully functional. Freshwater and wastewater can be handled by the chamber, or the chamber can be connected to local installations. All external freshwater and wastewater connections can be electrically heated to prevent freezing up to a limit of −20 °C. e air ow in the test chamber was designed to be non-recognizable at any seating position, in order to not provoke any adverse reactions due to the air ow (e. g. irritation to respiratory tract, nose or eyes). e air conditioning system installed allows the chamber temperature to be adjustable from 15 °C to 38 °C, and relative humidity levels can be set from 30 % to 80 % (non-condensing). Oxygen, carbon dioxide, carbon monoxide, and ozone levels are constantly monitored and recorded using calibrated sensors. e outside and chamber air is ltered using a multistage clean room lter system, removing almost any of PM 10 and PM 2.5 particles.
e environmental simulation capabilities of the GA 2 LEN chamber were tested and monitored at various outside temperatures ranging from −10 °C up to 35 °C and humidity levels from 27 % to 91 %, using internal redundant and calibrated humidity and temperature sensors. A camera and microphones monitor the test chamber and are accessible through the control so ware in the observation room. If included in the consent form, audio and video can be recorded, e. g. to run a post analysis on sneezing occurrences. Noise level measurements have been performed with a calibrated noise level analyzer.
e test chamber can accommodate up to nine patients in addition to a study nurse and a physician, providing chairs with adjustable footrests and surfaces that can be sanitized. Each chair is equipped with a small table, which can be used for folders or tablet PCs and provides micro-USB charging cables.
e chairs are at xed positions but can be removed for full cleaning. In order to reduce the cleaning time and allow individual verum/placebo exposure for each patient, particles in the GA 2 LEN chamber are not dispersed using conventional disperse and distribution technology, which would result in particles sticking to every surface in the room, including the ceiling, walls, and a generally hard-to-control exposure of each individual study subject. In the GA 2 LEN chamber, particles are only dispersed where the subjects are seated [18] , the chamber's airow is designed in a way that other surfaces cannot be reached by the particles, except the subject chairs, tables, the oor, and the subjects themselves. e subjects wear clean-room apparel to minimize the possible amount of allergens entering and leaving the chamber. e oor is laid out as double ooring, so particles reaching the oor will fall through a metal grid, which is the upper oor. Particles falling through the grid are then sucked through 1 of the 10 existing exhaust air outlets and removed via lters, or they will just stick to the lower oor. is air ow design also prevents particles from re oating even while people are moving within the chamber.
Particle dispersal
e particle dispersion system consists of nine individual and independent particle disperse units, called PDUs [19] , one at each seating position. e particle disperse rate of each individual PDU and the general control of each unit is realized through A B a central control so ware. is so ware also controls, monitors, and protocols the environmental settings and sensor values. Each PDU has its own particle source, which is a dedicated containment called particle containment tape (PCT). PCTs are manufactured using a newly designed device called particle line unit (PLU). A PDU can release particles of a PCT through a nozzle that is located above the patient. e nozzle can be moved in two dimensions (e. g. an elliptic pattern), with a con gurable period of 10 to 600 seconds. Before releasing the particles, the PDU guides the PCT through a scanning microscope. e PDU counts the number of particles or use the line width and line density to calculate the disperse amount. is data allows controlling the amount of particles to be released in nanogram per second or particles per second. Each image of the scanning microscope is stored for the possibility of a post validation analysis. e used and re-spooled PCTs are kept on le for any post validation analysis required.
Both, the PLU and the PDU are designed to handle particles between 0.1 µm and 100 µm. e particle concentration that a PDU can generate depends on the particle density of the PCT and the speed at which the PCT is emptied. e concentration to which a subject is exposed also depends on the distance of the patient from the nozzle. erefore, when a subject is seated, the height of the chair is adjusted so that the nostrils of the subject are at a de ned level, called the calibrated exposure height. A more detailed description of PDU, PCT and PLU can be found in the online supplementary material (Annex 1 and 2) at www.springermedizin.de/allergojournal.
Particle distribution
e particle distribution was measured using sedimentation stripes and a calibrated laser particle counter, with and without a patient being present. For these measurements, an average human-sized dummy was used as a substitute for a real patient. For pollen, particle distribution pattern was validated using 4,000 and 8,000 grains per m 3 as target concentrations and time points 0, start time plus 90 minutes, and start time plus 240 minutes. For house dust mite particles, the distribution pattern was validated at target concentration of 400 ng Der p 1 per m 3 . A total of 21 sedimentation stripes (12 mm × 20 mm) were used at each measurement and each seating position while con rmatory laser particle measurements were performed at each seat. Measurement duration was 15 minutes for sedimentation tests and also 15 minutes for laser particle counter tests. Sedimentation stripes used to validate pollen distribution were analyzed by counting pollen microscopically while sedimentation stripes used for house dust mite particle distribution were analyzed using multiplex arrays for indoor allergens (MARIA®) [20] . To validate that no particle from an actively exposed seating position can access the breathable air of another seat, one patient was actively exposed with 8,000 pollen grains per m 3 ; in addition, six sedimentation stripes were positioned at the nostrils of the dummy, which was seated at the neighboring, non-actively exposed position. Four more sedimentation stripes were positioned on the knees of the dummy. Another four sedimentation stripes were placed at each of the other surrounding seating surfaces. Similar tests were performed with house dust mite particles.
Clinical validation
e GA²LEN chamber has performed clinical validation runs for grass pollen (Phleum pratense), birch pollen (Betula pendula) and house dust mites (Dermatophagoides farinae, Dermatophagoides pteronyssinus). All tests were performed in Berlin, Germany, and were approved by the ethics committee of the Charité University Hospital, Berlin. Beside an atopic population, the participation of non-atopic subjects served as a control group for unspeci c symptoms.
To evaluate the ideal allergen concentration that was able to imitate the symptoms from natural exposure, the subjects have been provoked in exposures with di erent durations and amounts of allergens. erefore, PCTs were produced with Phleum pratense (Allergon AB, Ängelholm, Sweden) for exposures with 4,000 or 8,000 grains/m³ and durations of 90 up to 240 minutes; Betula pendula (Allergon AB, Ängelholm, Sweden) for exposures with 4,000, 8,000 or 16,000 grains/m³ for durations of 90 up to 240 minutes, as well as Dermatophagoides pteronyssinus and Dermatophagoides farinae (Laboratorios LETI S.L., Barcelona, Spain; mixture of whole bodies, body parts and fecal matter) for ex- 
Results
Chamber setup e GA 2 LEN chamber was transported several times, performing over 330 validation runs with almost 200 subjects being exposed at least one time. A full clinical validation for grass pollen has been published by Zuberbier et al. [21] . Basing the chamber design on standard-sized container frames allows for standard transportation methods by truck, ship, or train without the need for special transportation permits. Even though the chamber consists of two containers, it can be transported on a single truck. e setup duration of the chamber depends on outside conditions (e. g. wind, rain) and the quality of the site preparation. However, it was always as low as 4 h, while setting up the chamber could be performed by only two operators. So far, the containers were transported over 10,000 km in total. Whereas a crane truck proved to be more e cient for short range transport (< 1,000 km), a megatrailer, in combination with a mobile crane, improved the e ciency for long range transport. All transportation and handling of the chamber did not a ect the usability in any way, which can be underlined by the published reproducibility data [21] . e air conditioning system installed allows the chamber temperature to be adjustable from 15 °C to 38 °C, and relative humidity levels can be set from 30 % to 80 % (non-condensing). Since temperature and humidity levels can a ect the patients' general well-being during the exposure, inuence the severity of symptoms, and even elicit symptoms, it was decided to determine the standard test environment with 21 °C and 55 % relative humidity. At all environmental tests performed, this standard test environment was reached within less than 80 minutes. Also, in all tested outdoor conditions, the indoor test environment was stable for more than 5 hours, unbiased by the interim presence of patients. During test times, the temperature was within +0.8 K/−0.5 K relative to the target temperature and humidity was within +5 %/−3 %. Lowest stable indoor temperature was 15 °C, and 35 °C was the highest. At each exposure test performed, carbon dioxide and oxygen levels were kept at physiologically compatible levels, whereas carbon monoxide and ozone levels remained unchanged during the course of the test period in all performed environmental tests so far. e airspeed at each seating position at calibrated exposure height is below 3 cm per second and was not recognizable by any of the subjects so far. In the performed clinical validation trials no clinically signi cant irritation to respiratory tract, nose, or eyes were observed in any of the non-atopic subjects.
Particle dispersal and distribution
In its current version, the PDU can generate a resulting concentration for grass or birch pollen ranging from 500 to 16,000 grains per cubic meter in the breathable air. When using house dust mite raw material, concentrations of 10 µg/m 3 to 1,000 µg/m 3 can be generated. Over 400 PCTs, using Phleum pratense, Betula pendula, Dermatophagoides farinae, and Dermatophagoides pteronyssinus have been produced using a PLU and used by a PDU within the GA 2 LEN chamber.
e pollen concentration measured within the breathable air showed a variation of ±12.2 % of the target concentration, while intra-seat variation was ±13 %, whereas seat-to-seat variation was less than ±7 %. For house dust mite particles, the variation was ±30 % of the target concentration, while intra-seat variation was +100 %/−50 % and seat-to-seat variation ±36.5 % (Fig. 3) . No pollen particles were found on any of the sedimentation stripes placed on the dummy sitting next to an actively exposed subject and the allergen concentration for house dust mites were below recognition threshold (0.6 ng).
e discrete exposure and thus the lack of particles adhering to the walls, reduced the time needed to perform the cleaning protocol a er each test, which resulted in a fast turnaround time.
Regulations
e custom built, standard-sized container frames, chosen as the structural basis for the chamber, comply with the requirements of the EU common and EU member-speci c regulations with regard to transportation, housing, re hazards, and environmental safety. Noise level measurements in the test chamber showed an average and well tolerable level of 60 db(A) ±1 db(A) at the seating positions when all PDUs were active.
Discussion
Since the rst AECs were developed in the 1980s [7] , the model was continually evolved and the number of facilities increased to 15 AECs currently existing worldwide [17] . e GA²LEN chamber in its present form provides a novel technology for allergy research and clinical trials, allowing a unique, fast, and standardized multicenter approach. e general chamber setup allows for a cost-e ective transportation and exible accommodation. Even though the setup duration depends on outside conditions and appropriate site preparation, it was always as low as 4 h, when per-formed by two operators. Within all traditional allergen exposure systems, only the Mobile Environmental Exposure Chamber (mEEC™) from Inamax Research Inc. (Mississauga, Ontario, Canada) was also designed for the transportability needed in multicenter trials [22] . With 9 possible seats, the maximum capacity is lower than in other AECs [6] , but can be compensated by a fast turnaround time with multiple exposure runs per day. As required [7, 17] and already performed in other AECs [15, 23, 24] , temperature, humidity, and volumetric air ow rate are constantly monitored and recorded throughout the exposure within the GA²LEN chamber and have been in a narrow range of the target values for the entire time.
e chosen temperature of 21°C (+0.8K/−0.5K) is comparable with already published data from other exposure units [15, 23, 24] , whereas the relative humidity of 55 % shows a smaller variation with +5 % /−3 % compared to the reported ±10 %.
e built-in air-conditioner is able to generate a tightly controlled, standardized and comfortable environment at outside temperatures ranging from −10 °C up to 35 °C and the air ow was not recognizable by any of the subjects. Oxygen, carbon dioxide, carbon monoxide, and ozone levels are constantly monitored and recorded, but can currently not be systematically altered. Due to the e cacy of the used lter system and the applied maintenance interval, it is not necessary to monitor PM 10 and PM 2.5 . In contrast to most of the other existing chambers, where the allergen is dispersed via fans throughout the exposition room [6] , the GA²LEN chamber provides an individual exposure at every seating position. e new developed particle dispersion system consists of nine individual and independent PDUs [19] , and enables verum and placebo exposure simultaneously within one challenge. e PDU can release particles through a nozzle that is located above the patient. Upfront, the particles are guided through a dedicated imaging microscope, to calculate the amount of particles in nanogram per second or particles per second. is data allows to control the amount of particles to be released. e concentration to which a subject is exposed to, also depends on the distance of the patient from the nozzle. erefore, the height of the chair is adjusted when the patient is seated, so that the nostrils of the subject are at a de ned level. e allergen load for pollen measured within the breathable air showed an average variation of ±12.2 % of the target concentration. ese ndings are comparable with already published results from Ito et al. [24] and Hamasaki et al. [25] , with ±15 % and ±12 % variation during their exposure sessions. For house dust mite particles, the average variation was ±30 %. is di erence might be explained by the inhomogeneous particle sizes and density of the house dust mite particles. However, no significant di erences in the elicitation of symptoms were found during the clinical validation studies. Unlike in other chamber facilities, the spatial distribution cannot be measured throughout the whole test chamber, since the allergen disperse is discrete and targeted. erefore, we measured the seat-to-seat-variation, which was less than ±7 % for pollen and ±36.5 % for house dust mite particles. In addition, we determined the distribution within one seating position, which was ±13 % for pollen and +100/−50 % for house dust mite. Since up to date no other AEC is equipped with an individual, discrete pollen dispersal system, our ndings cannot be compared. e unpublished data from all clinical validation studies in the GA²LEN chamber leads to the conclusion that up from a threshold dose of allergens per m³ no further increase of symptom severity is achievable.
is was also reported from Zuberbier et al. [21] for the grass validation study, where concentrations of 4,000 and 8,000 grains/m³ elicited comparable results. To the authors' knowledge, all existing chambers that have validated house dust mite particles for their exposures did exclusively use Dermatophagoides pteronyssinus and monitor the Der p1 quantity in nanogram per m³. Since we used a mixture of the two most clinical relevant mite types Dermatophagoides pteronyssinus and Dermatophagoides farinae, our ndings are not directly comparable. In addition, our target concentration of 400 ng Der p1 per m³ is much higher than reported by other AECs [7, 26] , but still no adverse events or symptoms leading to cancellation of the exposure occurred during the validation studies. 
